GlassScriptPhysician profile
Newton P Allen
NPI 1063452399
$7,746.94
in general payments reported to CMS, 2019-2025
41 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $1,088 · 2021: $954 · 2022: $944 · 2023: $734 · 2024: $1,954 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,466.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,087.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $800.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $720.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $573.04 | 2021-2025 | Qulipta, Vraylar |
| Lilly USA, LLC | $358.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $283.83 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $263.36 | 2020-2025 | |
| Averitas Pharma INC. | $242.57 | 2024-2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $200.45 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $194.97 | 2023-2024 | |
| Amarin Pharma, INC. | $171.17 | 2020-2021 | |
| Astellas Pharma US INC | $160.58 | 2019-2020 | |
| Abbott Laboratories | $150.89 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $133.32 | 2023-2025 | Cologuard Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Newton Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.